The rapid growth of Alvogen is impressive by any standards, but for a company operating in the ever-changing pharmaceuticals market it is even more remarkable. The secret of Alvogen's success lies in its decision to expand and diversify its company function, its product line and its geographical markets.

After years of struggle, Spain's economy seems to have turned a corner. This is in no small part down to its burgeoning FDI markets, particularly in the financial services, property, manufacturing and construction sectors.

Allegations of corruption have dealt a blow to several international pharmaceutical companies operating in China. Despite this, the long-term prognosis for the industry remains good, with huge growth potential in what is set to become the world's second largest drugs market by 2016.

The Chinese city of Tianjin may lie in the shadow of investment behemoths Beijing and Shanghai, but it is still at the forefront of the country’s high-tech focus, with the Tianjin Economic-Technological Development Area central to its strong FDI appeal.

Investment into the state of New York is naturally dominated by New York City, leaving the likes of Buffalo and Rochester trailing in its wake. However, after years of decline, the two cities look to be on the cusp of a revival, thanks in no small part to the state governor's ambitious investment plans.

The US biotechnology landscape has changed radically in the 20 years since the first BIO International Convention. And while investment is still focused on a handful of states, other US destinations are bubbling under.

While the US continues to take the lion’s share of investment and projects in the biotech and pharmaceutical sectors, locations in Asia and Europe are increasingly attracting the attention of investors. 

Dubai’s free zones are drawing in businesses unfamiliar with the Middle East, thanks to a combination of an impressive infrastructure, sound business advice being on offer and low taxation.